This double‐blind, multicenter, randomized placebo‐controlled study evaluated the
antihypertensive efficacy and safety of nebivolol, a selective β1‐adrenoreceptor blocker with …

Nebivolol is a novel, β1-adrenergic receptor blocker with vasodilatory properties mediated
through the activation of the l-arginine/nitric oxide pathway. Short-term randomized clinical …

Background: The antihypertensive activity of beta-blockers generally increases during the
first 6 to 8 weeks of treatment; however, no study has systematically assessed whether blood …

Nebivolol has been adequately tested in clinical efficacy trials of patients with mild
hypertension. Clinical efficacy trials or their metaanalyses did not accurately predict the …

Purpose Our meta-analysis was undertaken to evaluate the efficacy and safety of nebivolol
compared with other second-generation β blockers for hypertensive patients. Methods We …

BACKGROUND: Nebivolol is a β1-selective β-blocker with NO-mediated vasodilatory
properties, approved in the United States for the treatment of stage I–II hypertension …

Abstract β-Adrenergic receptor blockers (β-blockers) are well-known useful and cost-
effective drugs for managing hypertensive patients with coronary heart disease, stroke, and …

Background and objective Lowering BP to normal levels without quality of life deterioration
is the most important means of reducing cardiovascular risk. Recent studies have …

Abstract▲ Nebivolol is a β-adrenergic receptor antagonist with a dual mechanism of action.
It shows high selectivity for β 1-adrenergic receptors and appears to have nitric oxide …

Background Nebivolol is a novel, β1‐adrenergic receptor blocker with vasodilatory
properties mediated through activation of the L‐arginine/nitric oxide pathway. Hypothesis …